Healthcare / BiotechnologyShenzhen
$16.79
-0.22 (-1.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $102.0M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.5B
P/E
76.3x
↑EV/EBITDA
31.5x
↑ROE
1.5%
↑Gross Margin
49.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.3%
FCF CAGR
—
FCF margin
-23.0%
FCF / Net income
-4.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.06B · net income $112.7M · FCF $-474.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.06B | $2.06B | $1.73B | $2.65B | $2.76B |
| Net Income | $112.7M | $112.7M | $397.0M | $237.5M | $432.2M |
| EBITDA | $256.7M | $256.7M | $581.4M | $452.7M | $629.7M |
| EPS | 0.22 | 0.22 | 0.79 | 0.47 | 0.86 |
| Gross Margin | 49.9% | 49.9% | 64.7% | 52.8% | 54.7% |
| Operating Margin | 16.6% | 16.6% | 26.8% | 21.0% | 18.8% |
| Net Margin | 5.5% | 5.5% | 22.9% | 9.0% | 15.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.32 | 6.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-474.1M | $-474.1M | $102.0M | $554.2M | $458.0M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 5.3% | 3.2% | 6.0% |
| Valuation | |||||
| P/E | 76.32 | 76.32 | 37.51 | 68.79 | 41.95 |
| EV/EBITDA | 31.52 | 31.52 | 23.40 | 31.80 | 26.42 |
| P/B | 1.16 | 1.16 | 1.99 | 2.23 | 2.52 |
| Growth & Yield | |||||
| Revenue Growth | 18.7% | 18.7% | -34.6% | -3.9% | — |
| EPS Growth | -72.2% | -72.2% | 68.1% | -45.3% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
89.2%
EPS terminal req.
$1.49
Spread vs growth
-161.3%
5Y implied EPS CAGR
52.3%
EPS terminal req.
$1.80
Spread vs growth
-124.5%
10Y implied EPS CAGR
29.4%
EPS terminal req.
$2.90
Spread vs growth
-101.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.6%
Start / end P/E
34.2x → 76.3x
EPS bridge
0.79 → 0.22
Residual
-88.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.